Stockscreener 앱 받기
41.29
0.43%
-0.18
시장 영업 전:
41.75
0.46
+1.11%
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Is Big Pharma's Patent Cliff Driving a New M&A Wave - Kavout | AI
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
E7P Forecast — Price Target — Prediction for 2027 - TradingView
A42086 Forecast — Price Target — Prediction for 2027 - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Canada
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior gains new overweight at Barclays on business turnaround - MSN
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Indivior (INDV) 10K Form and Latest SEC Filings 2026 - MarketBeat
Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds - Sahm
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
INDIVIOR PHARMACEUTICALS INC (INDV) Stock Chart - ChartMill
Indivior stock gains new Overweight at Barclays (INDV:NASDAQ) - Seeking Alpha
Barclays Initiates Indivior at Overweight With $46 Price Target - marketscreener.com
Indivior PLC (INDV) Institutional Confidence - TradingKey
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
How Strong SUBLOCADE Uptake And A $175M Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Suboxone Tooth Decay Lawsuit Updates for 2026 - Lawsuit Information Center
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
INDV Stock: What Sublocade Growth Signals for 2026 - The Globe and Mail
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026 - Yahoo Finance
Is Indivior Stock a Buy After Higher 2026 Guidance? - Yahoo Finance
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - The Globe and Mail
[144] Indivior Pharmaceuticals, Inc. SEC Filing - Stock Titan
A Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price Gains - Yahoo Finance
Indivior CFO Ryan Preblick sells $1.36m in company stock By Investing.com - Investing.com Australia
Indivior Pharmaceuticals Inc (INDV) CFO Ryan Preblick Sells 36,0 - GuruFocus
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
Indivior CFO Ryan Preblick sells $1.36m in company stock - Investing.com
Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing - Moomoo
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior: A Stronger Business Than When I First Covered It (NASDAQ:INDV) - Seeking Alpha
Amended Form 144: INDV (NASDAQ: INDV) lists 36,000-share sale via Fidelity - Stock Titan
INDV (NASDAQ) proposes sale of 36,000 shares; $1.36M aggregate listed - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Indivior (INDV) Hovers Near Resistance Amid Modest Gains – Key Levels in FocusOrder Block - newsline.com
Indivior Pharmaceuticals (INDV) Holds Steady Near Key Support Amidst Cautious TradingIchimoku Entry - newsline.com
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
Indivior PLC stock (GB00BYZ0C031): shares trade quietly as investors focus on valuation metrics - AD HOC NEWS
4.72%
1.13%
자본화:
|
볼륨(24시간):